Horizon Discovery Group plc Additional Listing (8753R)
15 December 2016 - 6:00PM
UK Regulatory
TIDMHZD
RNS Number : 8753R
Horizon Discovery Group plc
15 December 2016
15 December 2016
Horizon Discovery Group plc
Additional Listing
The Company has issued and allotted 13,358 new ordinary shares
of 1p each pursuant to the exercise of options.
Accordingly, an application has been made for 13,358 new
ordinary shares to be admitted to trading on AIM and it is expected
that admission will take place on 16 December 2016.
The new ordinary shares will rank pari passu with the existing
shares of the Company.
Following Admission, the Company's enlarged issued share capital
will comprise 95,245,817 ordinary shares with one voting right per
share. No shares are held in Treasury. The total number of voting
rights in the Company is therefore 95,245,817.
This figure of 95,245,817 ordinary shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Tel: +44 (0) 20 7653 4000
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter
almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and animal models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by c1,600 unique research organisations in over 50
countries as well as in the Company's own R&D pipeline to
support: a greater understanding of the genetic drivers of disease
and the development of molecular, cell and gene therapies that can
be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSDMMMZKDKGVZM
(END) Dow Jones Newswires
December 15, 2016 02:00 ET (07:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024